MICHELLE A FANALE to Radioimmunotherapy
This is a "connection" page, showing publications MICHELLE A FANALE has written about Radioimmunotherapy.
Connection Strength
0.198
-
Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma. Leuk Lymphoma. 2021 01; 62(1):58-67.
Score: 0.170
-
90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease. Br J Haematol. 2014 Oct; 167(2):207-13.
Score: 0.028